Equities

Bliss GVS Pharma Ltd

BLISSGVS:NSI

Bliss GVS Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)129.90
  • Today's Change5.10 / 4.09%
  • Shares traded1.28m
  • 1 Year change+41.43%
  • Beta0.6893
Data delayed at least 15 minutes, as of Sep 20 2024 11:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,5137261,459
Total Receivables, Net4,4514,2814,069
Total Inventory1,3661,5471,775
Prepaid expenses282432
Other current assets, total758396426
Total current assets8,1166,9747,760
Property, plant & equipment, net3,6943,7292,948
Goodwill, net777777
Intangibles, net1.072.293.83
Long term investments8757544
Note receivable - long term126158209
Other long term assets371843
Total assets12,13911,56911,087
LIABILITIES
Accounts payable610864926
Accrued expenses466226
Notes payable/short-term debt321460817
Current portion long-term debt/capital leases2281259.42
Other current liabilities, total393421552
Total current liabilities1,5981,9332,331
Total long term debt449434267
Total debt9981,0191,094
Deferred income tax36013
Minority interest358335278
Other liabilities, total262812
Total liabilities2,4672,7302,900
SHAREHOLDERS EQUITY
Common stock105104104
Additional paid-in capital332270213
Retained earnings (accumulated deficit)9,3948,6928,041
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(158)(227)(170)
Total equity9,6728,8398,187
Total liabilities & shareholders' equity12,13911,56911,087
Total common shares outstanding105104104
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.